Skip to main content

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

IMpella-Protected cArdiaC Surgery Trial (IMPACT)

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about IMpella-Protected cArdiaC Surgery Trial (IMPACT)

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in NMIBC

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in NMIBC

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Submitted by Anonymous (not verified) on Wed, 10/18/2023 - 19:26
  • Read more about Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Page 34
  • Page 35
  • …
  • Next page Next
  • Last page Last
Subscribe to